European intensive care physicians' experience of infections due to antibiotic-resistant bacteria.
Antimicrobial resistance
Antimicrobial treatment
Carbapenem-resistant Enterobacteriaceae
Intensive care
Meticillin-resistant Staphylococcus aureus
Third-generation-cephalosporin-resistant Enterobacteriaceae
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
09
2019
accepted:
10
12
2019
entrez:
8
1
2020
pubmed:
8
1
2020
medline:
14
7
2021
Statut:
epublish
Résumé
Antimicrobial resistance (AMR) compromises the treatment of patients with serious infections in intensive care units (ICUs), and intensive care physicians are increasingly facing patients with bacterial infections with limited or no adequate therapeutic options. A survey was conducted to assess the intensive care physicians' perception of the AMR situation in the European Union/European Economic Area (EU/EEA). Between May and July 2017, physicians working in European ICUs were invited to complete an online questionnaire hosted by the European Society of Intensive Care Medicine. The survey included 20 questions on hospital and ICU characteristics, frequency of infections with multidrug-resistant (MDR) bacteria and relevance of AMR in the respondent's ICU, management of antimicrobial treatment as well as the use of last-line antibiotics in the six months preceding the survey. For the analysis of regional differences, EU/EEA countries were grouped into the four sub-regions of Eastern, Northern, Southern and Western Europe. Overall, 1062 responses from four European sub-regions were analysed. Infections with MDR bacteria in their ICU were rated as a major problem by 257 (24.2%), moderate problem by 360 (33.9%) and minor problem by 391 (36.8%) respondents. Third-generation cephalosporin-resistant Enterobacteriaceae were the most frequently encountered MDR bacteria followed by, in order of decreasing frequency, meticillin-resistant The percentage of European ICU physicians perceiving AMR as a substantial problem in their ICU is high with variation by sub-region in line with epidemiological studies. The reports of bacteria resistant to almost all available antibiotics and the limited availability of last-line antibiotics in ICUs in the EU/EEA are of concern.
Sections du résumé
Background
Antimicrobial resistance (AMR) compromises the treatment of patients with serious infections in intensive care units (ICUs), and intensive care physicians are increasingly facing patients with bacterial infections with limited or no adequate therapeutic options. A survey was conducted to assess the intensive care physicians' perception of the AMR situation in the European Union/European Economic Area (EU/EEA).
Methods
Between May and July 2017, physicians working in European ICUs were invited to complete an online questionnaire hosted by the European Society of Intensive Care Medicine. The survey included 20 questions on hospital and ICU characteristics, frequency of infections with multidrug-resistant (MDR) bacteria and relevance of AMR in the respondent's ICU, management of antimicrobial treatment as well as the use of last-line antibiotics in the six months preceding the survey. For the analysis of regional differences, EU/EEA countries were grouped into the four sub-regions of Eastern, Northern, Southern and Western Europe.
Results
Overall, 1062 responses from four European sub-regions were analysed. Infections with MDR bacteria in their ICU were rated as a major problem by 257 (24.2%), moderate problem by 360 (33.9%) and minor problem by 391 (36.8%) respondents. Third-generation cephalosporin-resistant Enterobacteriaceae were the most frequently encountered MDR bacteria followed by, in order of decreasing frequency, meticillin-resistant
Conclusions
The percentage of European ICU physicians perceiving AMR as a substantial problem in their ICU is high with variation by sub-region in line with epidemiological studies. The reports of bacteria resistant to almost all available antibiotics and the limited availability of last-line antibiotics in ICUs in the EU/EEA are of concern.
Identifiants
pubmed: 31908772
doi: 10.1186/s13756-019-0662-8
pii: 662
pmc: PMC6941296
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1Informations de copyright
© The Author(s). 2019.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Clin Microbiol Infect. 2016 Feb;22(2):171-177
pubmed: 26498852
J Glob Antimicrob Resist. 2013 Sep;1(3):131-134
pubmed: 24749079
Clin Microbiol Infect. 2017 Oct;23(10):704-712
pubmed: 28893690
Infect Control Hosp Epidemiol. 2013 Mar;34(3):274-83
pubmed: 23388362
Clin Infect Dis. 2007 Mar 15;44(6):867-73
pubmed: 17304462
Intensive Care Med. 2017 Aug;43(8):1164-1166
pubmed: 28409204
Clin Microbiol Infect. 2011 Jan;17(1):80-7
pubmed: 20132254
Clin Infect Dis. 2012 Jan 15;54(2):268-74
pubmed: 22198992
Antimicrob Resist Infect Control. 2016 Nov 22;5:49
pubmed: 27895904
Euro Surveill. 2019 Nov;24(46):null
pubmed: 31771708
Crit Care. 2012 Nov 15;16(6):R221
pubmed: 23151325
Clin Microbiol Infect. 2017 Oct;23(10):695-696
pubmed: 28830808
Clin Infect Dis. 2011 Apr 1;52(7):848-55
pubmed: 21317398
Int J Environ Res Public Health. 2018 Dec 23;16(1):
pubmed: 30583571
Nat Microbiol. 2019 Nov;4(11):1919-1929
pubmed: 31358985
J Hosp Infect. 2015 Dec;91(4):338-45
pubmed: 26542950
Intensive Care Med. 2017 Sep;43(9):1187-1197
pubmed: 28160023
Euro Surveill. 2009 Nov 12;14(45):null
pubmed: 19941792
Eur J Clin Microbiol Infect Dis. 2019 Jul;38(7):1235-1240
pubmed: 30900056
Antimicrob Resist Infect Control. 2013 Mar 26;2(1):9
pubmed: 23531169
Clin Infect Dis. 2014 Jul 1;59(1):88-94
pubmed: 24700659
Clin Microbiol Infect. 2017 Sep;23(9):590-592
pubmed: 28522030
Ann Intensive Care. 2011 Nov 23;1:47
pubmed: 22112929
J Clin Microbiol. 2017 Mar;55(3):715-723
pubmed: 28031432